dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Yoshino, T. |
dc.contributor.author | Portnoy, D. C. |
dc.contributor.author | Obermannova, Radka |
dc.contributor.author | Bodoky, György |
dc.contributor.author | Prausová, J. |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Garcia-Carbonero, Rocio |
dc.date.accessioned | 2021-03-19T12:39:55Z |
dc.date.available | 2021-03-19T12:39:55Z |
dc.date.copyright | 2018 |
dc.date.issued | 2019-01-01 |
dc.identifier.citation | Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, et al. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Ann Oncol. 2019;30(1):124–31. |
dc.identifier.issn | 1569-8041 |
dc.identifier.uri | https://hdl.handle.net/11351/5778 |
dc.description | Carcinoma colorrectal; Ramucirumab; BRAF |
dc.description.sponsorship | This work was supported by Eli Lilly and Company. No grant number is applicable. |
dc.language.iso | eng |
dc.publisher | Oxford University Press |
dc.relation.ispartofseries | Annals of Oncology;30 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Còlon - Càncer |
dc.subject | Recte - Càncer |
dc.subject | Marcadors tumorals |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | Neoplasm Metastasis |
dc.subject.mesh | Biomarkers, Tumor |
dc.subject.mesh | /analysis |
dc.title | Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1093/annonc/mdy461 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | metástasis neoplásica |
dc.subject.decs | marcadores tumorales |
dc.subject.decs | /análisis |
dc.relation.publishversion | https://www.sciencedirect.com/science/article/pii/S0923753419309792 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Yoshino T] National Cancer Center Hospital East, Kashiwa, Japan. [Portnoy DC] The West Clinic, Memphis, USA. [Obermannová R] Masarykuv Onkologicky Ustav, Brno, Czech Republic. [Bodoky G] St. Laszlo Hospital, Budapest, Hungary. [Prausová J] Fakultni Nemocnice v MOTOLE, Prague, Czech Republic. [Garcia-Carbonero R] Hospital Hospital Universitario Doce de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERONC, Barcelona, Spain |
dc.identifier.pmid | 30339194 |
dc.identifier.wos | 000459677700018 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |